Capsaicin in Digital Osteoarthritis Versus Control

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · May 31, 2024

Keywords

ClinConnect Summary

Visit 0 : Screening visit (D0 - 30 days): Screen for eligibility

Visit 1 :Inclusion visit (D0): Randomization and blinded patch application of capsaicin 8% or 0.04%

Visit 2: Follow-up visit 1 (D60 + 7 days): Assessment +/- Patch renewal. Patients with finger pain still greater than 4/10 may receive an open application of a capsaicin 8%

Visit 3:Follow-up visit 2 (D120 +/- 7 days): Final assessment.

For the duration of the study, the patient will record in a notebook: analgesics, anti-inflammatories, corticoids and daily hand pain VAS.

Blood samples will be taken at V1 and V2 for subsequ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of digital osteoarthritis fulfilling the American College of Rheumatology criteria;
• • Presence of finger pain of ≥ 40 mm on a visual analogue scale (VAS);
• • Presence of finger pain with a neuropathic pain component (DN4 score ≥ 4/10)
• • Inadequate response, adverse reactions, and/or contraindications to conventional analgesics and NSAIDs;
• Exclusion Criteria:
• • Patient with isolated rhizarthrosis;
• • Patient with other joint disease affecting the fingers (gout, chondrocalcinosis, RA, spondyloarthritis, psoriatic arthritis);
• • Patient with upper extremity pain syndrome that may interfere with the assessment of finger pain;
• • Patient with another pathology responsible for neuropathic hand pain (carpal tunnel syndrome, diabetic neuropathy, Guyon's tunnel syndrome, cervicobrachial neuralgia, brachial plexitis);
• • Patient with skin lesions on the fingers (psoriasis, wounds, chronic ulcers, eczema, shingles, dermatitis);
• • Patient with poorly controlled high blood pressure;
• • Patient with hypersensitivity to capsaicin;
• • Patient who had 8% capsaicin patch use in the year prior to the study;
• • Patient who has received intramuscular, intra-articular or intravenous corticosteroid therapy, another disease-modifying anti-rheumatic therapy (methotrexate, salazopyrine) or an intra-articular injection into the joints of the fingers within the previous 3 months;
• • Patient wearing wrist or finger orthoses in the previous month;
• • Patient with fibromyalgia;

Trial Officials